Scott Tagawa, MD, MS, FACP, FASCO

Scott Tagawa, MD, highlights the PSMAddition trial's promising results, showcasing Lutetium-177 PSMA-617's significant benefits for advanced prostate cancer treatment.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the potential benefits of antibody-drug conjugates in urothelial cancer while acknowledging the need for more education and experience among physicians to optimize their use.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the importance of considering a drug's overall value beyond just its initial price per mg.

Scott T. Tagawa, MD, MS, FACP, FASCO, highlights a key difference between oral androgen receptor inhibitor drugs and therapeutic radionuclides for the treatment of prostate cancer.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses that patients with advanced prostate cancer benefit from a multidisciplinary care team.

Scott Tagawa, MD, MS, FACP wraps up by discussing how he envisions the future of prostate cancer and offers advice to community oncologists treating patients with the disease.

An overview of the barriers and challenges that patients, caregivers, clinicians, and other healthcare personnel may face when radiation-based therapies are used for treatment of prostate cancer.

Scott Tagawa, MD, MS, FACP, discusses other prostate cancer settings besides metastatic CRPC where Lu 177 vipivotide tetraxetan could potentially be useful, and touches on ongoing clinical trials in these settings.

A discussion of key safety data on the VISION trial.

Scott Tagawa, MD, MS, FACP, compares the use of single-agent regimens versus combination regimens in the treatment of metastatic prostate cancer.

Scott Tagawa, MD, MS, FACP, reviews key efficacy data from the VISION trial of Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (CRPC).

A comprehensive review of treatment options for metastatic prostate cancer, including PSMA-targeted therapies.

Scott Tagawa, MD, MS, FACP expands upon prostate-specific membrane antigen (PSMA)-based PET imaging modalities.

A focused discussion on how phenotypic biomarkers and positron emission tomography (PET)-based imaging can be combined to diagnose and treat prostate cancer.

Scott Tagawa, MD, MS, FACP reviews emerging phenotypic biomarker approaches that may complement genomic biomarker testing.

An overview of genomic biomarker testing approaches for patients with prostate cancer.

Scott Tagawa, MD, MS, FACP, comments on some of the clinical factors that impact diagnosis, prognosis, and treatment of prostate cancer.

Scott T. Tagawa, MD, FACP, shares clinical pearls and advice for the management of mCRPC.

An expert in prostate cancer comments on emerging agents and combinations in the pipeline for the treatment of mCRPC.

Scott T. Tagawa, MD, FACP, shares his thoughts on remaining questions for imaging and PSMA-targeted therapy for mCRPC.

Dr Scott T. Tagawa discusses common adverse events associated with 177Lu-PSMA-617 in patients with mCRPC and how to appropriately manage them.

A prostate cancer expert considers clinical implications from the phase 3 VISION study, including the potential role of 177Lu-PSMA-617 therapy for patients with mCRPC.

Scott T. Tagawa, MD, FACP, reviews the phase 3 VISION trial evaluating the use of 177Lu-PSMA-617 therapy in patients with mCRPC.

An expert in prostate cancer reviews available options for the treatment of mCRPC and considerations for selecting the optimal therapy.

Dr Scott T. Tagawa reviews traditional imaging techniques and advances in imaging used in clinical practice for prostate cancer.

Scott T. Tagawa, MD, FACP, discusses the heterogeneity and features of prostate cancer and provides insight on biomarker testing.

Scott T. Tagawa, MD, MS, discusses a phase I dose-escalation study of actinium-225 in patients with progressive metastatic castration-resistant prostate cancer who had previously received at least 1 pathway inhibitor.

Scott T. Tagawa, MD, MS, medical director, Genitourinary Oncology Research Program, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses the baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC).

Scott T. Tagawa, MD, MS, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses PSMA-targeting agents for the treatment of prostate cancer.

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses results from a trial that evaluated tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) when using the Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.